$ESPR
Esperion Therapeutics, Inc. Stock $espr

$espr Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000162828021021092 Filed on November 02, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$15.40M	$14.41M	$3.833M
YoY Change	59.79%	275.92%	290.72%
Cost Of Revenue	$5.075M	$5.558M	$300.0K
YoY Change	198.53%	1752.67%
Gross Profit	$10.33M	$8.851M	$3.600M
YoY Change	29.08%	145.86%
Gross Profit Margin	67.05%	61.43%	93.92%
Selling, General & Admin	$25.09M	$39.27M	$48.83M
YoY Change	-59.24%	-19.58%	164.38%
% of Gross Profit	242.96%	443.62%	1356.28%
Research & Development	$27.62M	$25.33M	$35.28M
YoY Change	-34.19%	-28.21%	-26.92%
% of Gross Profit	267.44%	286.19%	980.08%
Depreciation & Amortization	$153.0K	$153.0K	$170.0K
YoY Change	-4.38%	-10.0%	88.89%
% of Gross Profit	1.48%	1.73%	4.72%
Operating Expenses	$52.70M	$70.15M	$84.38M
YoY Change	-49.9%	-16.86%	26.42%
Operating Profit	-$42.38M	-$55.75M	-$80.55M
YoY Change	-55.66%	-30.8%	22.48%
Interest Expense	-$13.43M	$13.65M	$4.928M
YoY Change	-250.38%	177.07%	23.32%
% of Operating Profit
Other Income/Expense, Net	$3.939M	$13.00K	$42.00K
YoY Change	16312.5%	-69.05%	-96.97%
Pretax Income	-$65.12M	-$69.39M	-$85.40M
YoY Change	-37.69%	-18.75%	24.85%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$65.12M	-$69.39M	-$85.44M
YoY Change	-37.67%	-18.79%	24.95%
Net Earnings / Revenue	-422.82%	-481.55%	-2228.99%
Basic Earnings Per Share		-$2.62	-$3.07
Diluted Earnings Per Share	-$1.763M	-$2.62	-$3.07
COMMON SHARES
Basic Shares Outstanding	29.08M shares	26.46M shares	27.83M shares
Diluted Shares Outstanding		26.46M shares	27.83M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$259.3M	$103.7M	$215.7M
YoY Change	-14.96%	-51.95%	-11.53%
Cash & Equivalents	$208.9M	$103.7M	$215.7M
Short-Term Investments	$50.44M		$0.00
Other Short-Term Assets	$12.31M	$11.31M	$18.00M
YoY Change	-50.36%	-37.14%	87.5%
Inventory	$34.39M	$33.97M	$9.061M
Prepaid Expenses
Receivables	$22.93M	$21.71M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$329.0M	$170.7M	$242.8M
YoY Change	-4.89%	-29.71%	-4.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$664.0K	$817.0K	$1.408M
YoY Change	-47.96%	-41.97%	46.97%
Goodwill
YoY Change
Intangibles	$56.00K
YoY Change	0.0%
Long-Term Investments
YoY Change
Other Assets	$50.00M	$50.00M	$56.00K
YoY Change		89185.71%
Total Long-Term Assets	$52.62M	$54.59M	$8.166M
YoY Change	614.72%	568.48%	351.16%
TOTAL ASSETS
Total Short-Term Assets	$329.0M	$170.7M	$242.8M
Total Long-Term Assets	$52.62M	$54.59M	$8.166M
Total Assets	$381.6M	$225.3M	$251.0M
YoY Change	8.02%	-10.25%	-1.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.56M	$20.75M	$17.58M
YoY Change	-66.22%	17.98%	-25.92%
Accrued Expenses	$38.82M	$40.62M	$45.80M
YoY Change	10.9%	-11.3%	46.79%
Deferred Revenue	$5.683M	$3.068M	$1.662M
YoY Change	241.94%	84.6%	-36.52%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$73.35M	$78.49M	$75.95M
YoY Change	-22.02%	3.34%	32.04%
LONG-TERM LIABILITIES
Long-Term Debt	$258.3M	$272.5M	$0.00
YoY Change	43.97%
Other Long-Term Liabilities	$0.00	$1.290M	$1.710M
YoY Change	-100.0%	-24.56%	-98.68%
Total Long-Term Liabilities	$0.00	$1.290M	$1.710M
YoY Change	-100.0%	-24.56%	-98.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$73.35M	$78.49M	$75.95M
Total Long-Term Liabilities	$0.00	$1.290M	$1.710M
Total Liabilities	$578.5M	$588.0M	$242.0M
YoY Change	28.74%	142.95%	29.58%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.106B	-$1.041B	-$734.3M
YoY Change	31.9%	41.79%	15.95%
Common Stock	$61.00K	$27.00K	$28.00K
YoY Change	134.62%	-3.57%	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$55.00M	$55.00M
YoY Change	0.0%
Treasury Stock Shares	1.994M shares	1.994M shares
Shareholders Equity	-$196.9M	-$362.7M	$8.960M
YoY Change
Total Liabilities & Shareholders Equity	$381.6M	$225.3M	$251.0M
YoY Change	8.02%	-10.25%	-1.68%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$65.12M	-$69.39M	-$85.44M
YoY Change	-37.67%	-18.79%	24.95%
Depreciation, Depletion And Amortization	$153.0K	$153.0K	$170.0K
YoY Change	-4.38%	-10.0%	88.89%
Cash From Operating Activities	-$57.71M	-$69.17M	-$86.67M
YoY Change	-15.82%	-20.19%	49.35%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$90.00K
YoY Change	-100.0%	-100.0%	-125.0%
Acquisitions
YoY Change
Other Investing Activities	-$50.48M	$0.00	$2.250M
YoY Change		-100.0%	-145.36%
Cash From Investing Activities	-$50.48M	$0.00	$2.330M
YoY Change	298.45%	-100.0%	-143.88%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	213.4M	3.655M	1.600M
YoY Change	25.21%	128.44%	64.95%
NET CHANGE
Cash From Operating Activities	-57.71M	-69.17M	-86.67M
Cash From Investing Activities	-50.48M	0.000	2.330M
Cash From Financing Activities	213.4M	3.655M	1.600M
Net Change In Cash	105.2M	-65.51M	-82.74M
YoY Change	17.93%	-20.82%	32.66%
FREE CASH FLOW
Cash From Operating Activities	-$57.71M	-$69.17M	-$86.67M
Capital Expenditures	$0.00	$0.00	$90.00K
Free Cash Flow	-$57.71M	-$69.17M	-$86.76M
YoY Change	3.29%	-20.28%	50.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001434868
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
CY2020	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	espr:AccountingStandardsUpdate202006Member
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-35986
	dei	Entity Registrant Name EntityRegistrantName	Esperion Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1870780
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3891 Ranchero Drive, Suite 150
	dei	Entity Address City Or Town EntityAddressCityOrTown	Ann Arbor
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48108
	dei	City Area Code CityAreaCode	734
	dei	Local Phone Number LocalPhoneNumber	887-3903
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	ESPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29077357	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103672000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21710000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12388000	USD
CY2021Q3	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	986000	USD
CY2020Q4	espr	Prepaid Clinical Development Costs Current PrepaidClinicalDevelopmentCostsCurrent	844000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	33972000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10328000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11566000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	170668000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	345896000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	50000000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	817000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1276000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3715000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6030000	USD
CY2021Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	56000	USD
CY2021Q3	us-gaap	Assets Assets	225256000	USD
CY2020Q4	us-gaap	Assets Assets	353258000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	20745000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	51975000	USD
CY2021Q3	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	3746000	USD
CY2020Q4	espr	Accrued Clinical Development Costs Current AccruedClinicalDevelopmentCostsCurrent	7663000	USD
CY2021Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	34476000	USD
CY2020Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24790000	USD
CY2021Q3	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	14048000	USD
CY2020Q4	espr	Revenue Interest Liability Current RevenueInterestLiabilityCurrent	5392000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3068000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1662000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2402000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2587000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	78485000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94069000	USD
CY2021Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	272508000	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	179367000	USD
CY2021Q3	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	233520000	USD
CY2020Q4	espr	Revenue Interest Liability Noncurrent RevenueInterestLiabilityNoncurrent	171212000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1313000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3454000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	845000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1290000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1290000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	587961000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	449392000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28794567	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27910366	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	26000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	733524000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	797655000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	1994198	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	54998000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1041258000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-838817000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-362705000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	225256000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	353258000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14409000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3833000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63046000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	217909000	USD
CY2021Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	5558000	USD
CY2020Q3	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	275000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	9142000	USD
	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	704000	USD
CY2021Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	25331000	USD
CY2020Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	35283000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	78359000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	104972000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	39265000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	48826000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	146647000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	138060000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	70154000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	84384000	USD
	us-gaap	Operating Expenses OperatingExpenses	234148000	USD
	us-gaap	Operating Expenses OperatingExpenses	243736000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-55745000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-80551000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-171102000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25827000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	13654000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4928000	USD
	us-gaap	Interest Expense InterestExpense	32923000	USD
	us-gaap	Interest Expense InterestExpense	13739000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	42000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	491000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-69386000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-85437000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-203989000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39075000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.62
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.62
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.07
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.41
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.41
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26455209	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26455209	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27830281	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27830281	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	26225730	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	26225730	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27672325	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27672325	shares
CY2021Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2020Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-23000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69386000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-85437000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-203989000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39098000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19950000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1014000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7053000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-14000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-78249000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-50246000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3738000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7395000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	124611000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	85489000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1644000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7264000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-85437000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	8960000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-96134000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2668000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1183000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5751000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-90935000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-269394000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	168000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	0	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8584000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-43668000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-304310000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4207000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	375000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	912000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5497000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-69386000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-362705000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-203989000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39075000	USD
	us-gaap	Depreciation Depreciation	459000	USD
	us-gaap	Depreciation Depreciation	387000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	97000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1214000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	23310000	USD
	espr	Non Cash Interest Expense Related To Revenue Interest Liability NonCashInterestExpenseRelatedToRevenueInterestLiability	13739000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	19832000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21712000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9322000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5787000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1096000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2202000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2251000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-490000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	17836000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9061000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1710000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-30833000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-11326000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	7715000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	13863000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206103000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16627000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4420000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39145000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	693000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	34032000	USD
	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	49917000	USD
	espr	Proceeds From Revenue Interest Purchase Agreement Net Of Issuance Costs ProceedsFromRevenueInterestPurchaseAgreementNetOfIssuanceCosts	25000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4388000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3211000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6395000	USD
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	2263000	USD
	espr	Payments From Revenue Interest Purchase Agreement PaymentsFromRevenueInterestPurchaseAgreement	110000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	440000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54813000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	31285000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-151290000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	48690000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153672000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215748000	USD
	espr	Common Stock Issuance Costs Incurred CommonStockIssuanceCostsIncurred	181000	USD
	espr	Common Stock Issuance Costs Incurred CommonStockIssuanceCostsIncurred	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	148000	USD
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	10000	USD
	espr	Non Cash Right Of Use Asset NonCashRightOfUseAsset	3000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	50000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div>
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	50000000	USD
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of September 30, 2021, ten customers accounted for all of the Company's net trade receivables and as of December 31, 2020 eight customers accounted for all the Company's net trade receivables.</span></div>
	espr	Number Of Sources Of Revenue NumberOfSourcesOfRevenue	2	revenue_source
CY2021Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	30282000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13788000	USD
CY2021Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1302000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2028000	USD
CY2021Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2388000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	320000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	33972000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	16136000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	130766000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	130766000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	281783000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	281783000	USD
CY2021Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q3	us-gaap	Accrued Investment Income Receivable AccruedInvestmentIncomeReceivable	0	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	USD
CY2020Q4	us-gaap	Payments For Derivative Instrument Financing Activities PaymentsForDerivativeInstrumentFinancingActivities	46000000	USD
CY2020Q4	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	55000000	USD
CY2020Q4	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	1994198	shares
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10920000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15161000	USD
CY2021Q3	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	14239000	USD
CY2020Q4	espr	Accrued Variable Consideration Current AccruedVariableConsiderationCurrent	5025000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5069000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3183000	USD
CY2021Q3	us-gaap	Interest Payable Current InterestPayableCurrent	4200000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1369000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	52000	USD
CY2021Q3	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	34476000	USD
CY2020Q4	espr	Accrued Liabilities And Employee Related Liabilities Current AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent	24790000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4176518	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.24
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M10D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	18415000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	757992	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	28.06
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1001831	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	48.92
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	228741	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.04
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3703938	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	37.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M19D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2708000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3703938	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	37.02
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y2M19D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2708000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2947780	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	37.21
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y1M9D
CY2021Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2708000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13098695	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4886260	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	103672000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215748000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	304962000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166130000	USD
CY2021Q3	us-gaap	Restricted Cash RestrictedCash	50000000	USD
CY2020Q3	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2019Q4	us-gaap	Restricted Cash RestrictedCash	928000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153672000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	304962000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	167058000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	215748000	USD
CY2021Q3	espr	Sale Of Stock Maximum Value Of Shares Issued In Transaction SaleOfStockMaximumValueOfSharesIssuedInTransaction	250000000	USD
CY2021Q3	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	363061	shares
CY2021Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	4200000	USD

Files In Submission

Name	View Source	Status
0001628280-21-021092-index-headers.html	Edgar Link	pending
0001628280-21-021092-index.html	Edgar Link	pending
0001628280-21-021092.txt	Edgar Link	pending
0001628280-21-021092-xbrl.zip	Edgar Link	pending
espr-20210930.htm	Edgar Link	pending
espr-20210930.xsd	Edgar Link	pending
espr-20210930_cal.xml	Edgar Link	unprocessable
espr-20210930_def.xml	Edgar Link	unprocessable
espr-20210930_htm.xml	Edgar Link	completed
espr-20210930_lab.xml	Edgar Link	unprocessable
espr-20210930_pre.xml	Edgar Link	unprocessable
espr-ex311x09302021.htm	Edgar Link	pending
espr-ex312x09302021.htm	Edgar Link	pending
espr-ex321x09302021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ESPR
Esperion Therapeutics, Inc. Stock $espr

2021 Q4 Form 10-Q Financial Statement

#000162828021021092 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR Esperion Therapeutics, Inc. Stock $espr

2021 Q4 Form 10-Q Financial Statement

#000162828021021092 Filed on November 02, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ESPR
Esperion Therapeutics, Inc. Stock $espr